Browse ITIH3

Summary
SymbolITIH3
Nameinter-alpha-trypsin inhibitor heavy chain 3
Aliases H3P; pre-alpha (globulin) inhibitor, H3 polypeptide; inter-alpha-trypsin inhibitor heavy chain H3; inter-alp ......
Chromosomal Location3p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF06668 Inter-alpha-trypsin inhibitor heavy chain C-terminus
PF08487 Vault protein inter-alpha-trypsin domain
PF00092 von Willebrand factor type A domain
Function

May act as a carrier of hyaluronan in serum or as a binding protein between hyaluronan and other matrix protein, including those on cell surfaces in tissues to regulate the localization, synthesis and degradation of hyaluronan which are essential to cells undergoing biological processes.

> Gene Ontology
 
Biological Process GO:0002576 platelet degranulation
GO:0006022 aminoglycan metabolic process
GO:0006887 exocytosis
GO:0010466 negative regulation of peptidase activity
GO:0010951 negative regulation of endopeptidase activity
GO:0030203 glycosaminoglycan metabolic process
GO:0030212 hyaluronan metabolic process
GO:0045055 regulated exocytosis
GO:0045861 negative regulation of proteolysis
GO:0051346 negative regulation of hydrolase activity
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:1903510 mucopolysaccharide metabolic process
Molecular Function GO:0004857 enzyme inhibitor activity
GO:0004866 endopeptidase inhibitor activity
GO:0004867 serine-type endopeptidase inhibitor activity
GO:0030414 peptidase inhibitor activity
GO:0061134 peptidase regulator activity
GO:0061135 endopeptidase regulator activity
Cellular Component GO:0030141 secretory granule
GO:0031089 platelet dense granule lumen
GO:0031983 vesicle lumen
GO:0034774 secretory granule lumen
GO:0042827 platelet dense granule
GO:0060205 cytoplasmic membrane-bounded vesicle lumen
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-109582: Hemostasis
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
Summary
SymbolITIH3
Nameinter-alpha-trypsin inhibitor heavy chain 3
Aliases H3P; pre-alpha (globulin) inhibitor, H3 polypeptide; inter-alpha-trypsin inhibitor heavy chain H3; inter-alp ......
Chromosomal Location3p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ITIH3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolITIH3
Nameinter-alpha-trypsin inhibitor heavy chain 3
Aliases H3P; pre-alpha (globulin) inhibitor, H3 polypeptide; inter-alpha-trypsin inhibitor heavy chain H3; inter-alp ......
Chromosomal Location3p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ITIH3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolITIH3
Nameinter-alpha-trypsin inhibitor heavy chain 3
Aliases H3P; pre-alpha (globulin) inhibitor, H3 polypeptide; inter-alpha-trypsin inhibitor heavy chain H3; inter-alp ......
Chromosomal Location3p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ITIH3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.5430.433
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2280.838
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.7920.391
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0890.844
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.8990.485
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9340.562
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0280.975
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6510.595
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.0570.418
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.8440.168
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 283.0160.0951
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.660.0158
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ITIH3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277305.5-5.50.572
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275906.8-6.80.304
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382713.2013.20.0705
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.6013.60.279
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.5012.50.485
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolITIH3
Nameinter-alpha-trypsin inhibitor heavy chain 3
Aliases H3P; pre-alpha (globulin) inhibitor, H3 polypeptide; inter-alpha-trypsin inhibitor heavy chain H3; inter-alp ......
Chromosomal Location3p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ITIH3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolITIH3
Nameinter-alpha-trypsin inhibitor heavy chain 3
Aliases H3P; pre-alpha (globulin) inhibitor, H3 polypeptide; inter-alpha-trypsin inhibitor heavy chain H3; inter-alp ......
Chromosomal Location3p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ITIH3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ITIH3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolITIH3
Nameinter-alpha-trypsin inhibitor heavy chain 3
Aliases H3P; pre-alpha (globulin) inhibitor, H3 polypeptide; inter-alpha-trypsin inhibitor heavy chain H3; inter-alp ......
Chromosomal Location3p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ITIH3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolITIH3
Nameinter-alpha-trypsin inhibitor heavy chain 3
Aliases H3P; pre-alpha (globulin) inhibitor, H3 polypeptide; inter-alpha-trypsin inhibitor heavy chain H3; inter-alp ......
Chromosomal Location3p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ITIH3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolITIH3
Nameinter-alpha-trypsin inhibitor heavy chain 3
Aliases H3P; pre-alpha (globulin) inhibitor, H3 polypeptide; inter-alpha-trypsin inhibitor heavy chain H3; inter-alp ......
Chromosomal Location3p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ITIH3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolITIH3
Nameinter-alpha-trypsin inhibitor heavy chain 3
Aliases H3P; pre-alpha (globulin) inhibitor, H3 polypeptide; inter-alpha-trypsin inhibitor heavy chain H3; inter-alp ......
Chromosomal Location3p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ITIH3 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ITIH3.
ID Name Drug Type Targets #Targets
DB01593ZincSmall MoleculeA1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......119